BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-636@pharmaconomics
DTSTAMP:20260707T041630Z
DTSTART;VALUE=DATE:20260611
DTEND;VALUE=DATE:20260612
SUMMARY:SLN Phase 1 — divesiran (estimated date)
DESCRIPTION:Phase 1 trial results for divesiran in polycythemia vera are due ~ Jun 11\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1479615/000119312526279577/sln-ex99_1.htm\n\nTrack it: https://pharmaconomics.com/e/636
URL:https://pharmaconomics.com/e/636
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:SLN catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR